Concert Pharmaceuticals, Inc. (CNCE) News

Concert Pharmaceuticals, Inc. (CNCE): $4.27

0.06 (+1.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CNCE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter CNCE News Items

CNCE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CNCE News Highlights

  • For CNCE, its 30 day story count is now at 2.
  • Over the past 7 days, the trend for CNCE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BEAT are the most mentioned tickers in articles about CNCE.

Latest CNCE News From Around the Web

Below are the latest news stories about Concert Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNCE as an investment opportunity.

Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022

LEXINGTON, Mass., February 24, 2022--Concert to report 2021 financial results before the markets open on March 3, 2022.

Yahoo | February 24, 2022

Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

LEXINGTON, Mass., January 04, 2022--Concert completed patient enrollment in the CTP-543 THRIVE-AA2 Phase 3 trial for alopecia areata.

Yahoo | January 4, 2022

Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference

LEXINGTON, Mass., January 03, 2022--Concert to Participate in the H.C. Wainwright BIOCONNECT Conference.

Yahoo | January 3, 2022

Is Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Popular Amongst Institutions?

Every investor in Concert Pharmaceuticals, Inc. ( NASDAQ:CNCE ) should be aware of the most powerful shareholder...

Yahoo | December 31, 2021

Implied Volatility Surging for Concert Pharmaceuticals (CNCE) Stock Options

Investors need to pay close attention to Concert Pharmaceuticals (CNCE) stock based on the movements in the options market lately.

Yahoo | December 29, 2021

Roger D. Tung Sells 6,700 Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Stock

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) CEO Roger D. Tung sold 6,700 shares of the companys stock in a transaction dated Monday, December 13th. The shares were sold at an average price of $3.62, for a total transaction of $24,254.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this []

Dakota Financial News | December 16, 2021

Marshall Wace LLP Trims Stake in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)

Marshall Wace LLP reduced its position in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 61.2% in the 2nd quarter, Holdings Channel reports. The firm owned 20,455 shares of the biotechnology companys stock after selling 32,226 shares during the period. Marshall Wace LLPs holdings in Concert Pharmaceuticals were worth $86,000 as of its most recent filing with the []

Dakota Financial News | December 3, 2021

Vanguard Group Inc. Has $5.22 Million Position in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)

Vanguard Group Inc. lessened its stake in shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 10.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,238,016 shares of the biotechnology companys stock after selling 152,050 shares during the period. Vanguard Group Inc. owned 3.85% of Concert []

Dakota Financial News | November 21, 2021

Truist Securiti Research Analysts Increase Earnings Estimates for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Stock analysts at Truist Securiti increased their FY2021 earnings per share estimates for Concert Pharmaceuticals in a research note issued on Tuesday, November 9th. Truist Securiti analyst J. Lee now expects that the biotechnology company will post earnings of ($1.89) per share for the year, up from their prior estimate []

Dakota Financial News | November 14, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5289 seconds.